Role and significance of Erythroferrone level in chronic kidney diseases

Background Chronic Kidney Disease (CKD) is an escalating worldwide health issue, characterized by kidney damage or a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² persisting for three months or more . CKD is becoming acknowledged as a complicated worldwide health issue,, characterized by anemia due to erythropoietin insufficiency and diminished iron availability. Erythroferrone (ERFE), a hormone produced by erythroblasts, acts as a hepcidin inhibitor, enhancing iron uptake and mobilization, hence stimulating erythropoiesis. Aim To study ERFE level in CKD patients and its correlation with iron parameters in these patients. Methods The study was conducted on 60 subjects divided into 40 patients diagnosed with CKD and 20 subjects matched for patients age and sex as control group. Serum Erythroferrone level was assessed by enzyme-linked immunosorbent assay (ELISA). Results Results revealed that patients with CKD showed statistically significant increase in serum ERFE when compared to control group) P <0.001). There was weak negative correlation between ERFE and Hemoglobin . Conclusion Erythroferrone serves as an effective biomarker for evaluating anemia in chronic kidney disease (CKD) and its association with iron parameters in affected individuals; it also functions as a hemostatic hormone regulating plasma iron concentrations and total body iron stores.